Kite’s Tecartus Boxed Warning Will More Closely Resemble Other CAR-Ts After FDA Changes Course

 
• By Derrick Gingery

Tecartus label still will not state that secondary malignancy cases have been reported in patients who received the product. CBER officials also address causality questions in a NEJM paper.

CAR-T cells
FDA officials said in a NEJM article that new strategies could lower the risk of secondary malignancy after CAR-T therapy. • Source: Shutterstock

More from Cell & Gene Therapies

More from Advanced Technologies